Suchergebnisse - %22IgA%22

PubPharm (426)

1

Glycoprotein Nonmetastatic Melanoma Protein B (GPNMB) Immunohistochemistry Can Be a Useful Ancillary Tool to Identify Perivascular Epithelioid Cell Tumor

enthalten in: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc | 2024

von Wangsiricharoen, S. | Ingram, D. | Morey, R. | +3

2

Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy : insights from the NEFIGAN trial

enthalten in: Kidney international | 2024

von Wimbury, D. | Muto, M. | Bhachu, J. | +12

3

A narrative review of potential drug treatments for nephritis in children with IgA vasculitis (HSP)

enthalten in: Clinical rheumatology | 2023

von Williams, C. | Lamond, M. | Marro, J. | +2

4

A pediatric case of IgA nephropathy benefitting from targeted release formulation-budesonide

enthalten in: Pediatric nephrology (Berlin, Germany) | 2023

von Antonucci, L. | Colucci, M. | Emma, F. | +1

5

Concurrent fabry disease and immunoglobulin a nephropathy : a case report

enthalten in: BMC nephrology | 2023

von Zhou, L. | Dong, S. | Zhang, S. | +2

6

Effect of oral vitamin A supplementation on host immune response to infectious bronchitis virus infection in specific pathogen-free chicken

enthalten in: Poultry science | 2023

von Zhang, L. | Hou, Y. | Ma, Z. | +7

7

Proposal to Screen for Zinc and Selenium in Patients with IgA Deficiency

enthalten in: Nutrients | 2023

von Abu Jamra, S. | Komatsu, C. | Barbosa, F. | +2

8

Deciphering prognostic value of CD22 and its contribution to suppression of proinflammatory cytokines production in patients with IgA nephropathy

enthalten in: Immunology letters | 2023

von Liu, Y. | Li, H. | Yu, H. | +4

9

Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

enthalten in: Kidney international | 2023

von Barratt, J. | Lafayette, R. | Kristensen, J. | +110

CommentIn: Kidney Int. 2023 Feb;103(2):258-261. - PMID 36681455

10

Safety, efficacy and pharmacokinetics of sparsentan in pediatric subjects with selected kidney diseases. : A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects with Selected Proteinuric Glomerular Diseases (EPPIK). - EPPIK

enthalten in: WHO International Clinical Trials Registry Platform | 2023

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[43]